Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan L Kaufman

Showing results (11-20 of 145) with videos related to

Pageof 15
Sort By:
Clinical Lymphoma & Myeloma|March 2, 2006
Novel treatment approaches for patients with multiple myelomaRajni Sinha, Jonathan L Kaufman, Sagar Lonial
Clinical Lymphoma & Myeloma|May 27, 2008
Multiple myeloma presenting with advanced renal failure: a case report and new treatment optionsS Pierson Gladney, Sagar Lonial, Jonathan L Kaufman
British Journal of Haematology|March 16, 2025
BCL2 inhibition for multiple myeloma and AL amyloidosisLorenzo Cani, Vikas A Gupta, Jonathan L Kaufman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Glücksklee, the Quad, and High-Risk MyelomaAjay K Nooka, Jonathan L Kaufman, Sagar Lonial
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2004
IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNAWilliam J Kaiser, Jonathan L Kaufman, Margaret K Offermann
Lancet (London, England)|June 8, 2019
Registering a CD38 antibody upfront for multiple myelomaCraig C Hofmeister, Ajay Nooka, Jonathan L Kaufman, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapyJonathan L Kaufman, Claire Fabre, Sagar Lonial, et al.
Blood and Lymphatic Cancer : Targets and Therapy|March 19, 2021
BCL2 Family Inhibitors in the Biology and Treatment of Multiple MyelomaVikas A Gupta, James Ackley, Jonathan L Kaufman, et al.
Cancer|March 29, 2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studiesR Donald Harvey, Chao Zhang, Sagar Lonial, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case reportNicole Wilson, Minal Surati, Bruce F Walker, et al.
Pageof 15

Showing results (11-20 of 145) with videos related to

Sort By:
Pageof 15
Clinical Lymphoma & Myeloma|March 2, 2006
Novel treatment approaches for patients with multiple myelomaRajni Sinha, Jonathan L Kaufman, Sagar Lonial
Clinical Lymphoma & Myeloma|May 27, 2008
Multiple myeloma presenting with advanced renal failure: a case report and new treatment optionsS Pierson Gladney, Sagar Lonial, Jonathan L Kaufman
British Journal of Haematology|March 16, 2025
BCL2 inhibition for multiple myeloma and AL amyloidosisLorenzo Cani, Vikas A Gupta, Jonathan L Kaufman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Glücksklee, the Quad, and High-Risk MyelomaAjay K Nooka, Jonathan L Kaufman, Sagar Lonial
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2004
IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNAWilliam J Kaiser, Jonathan L Kaufman, Margaret K Offermann
Lancet (London, England)|June 8, 2019
Registering a CD38 antibody upfront for multiple myelomaCraig C Hofmeister, Ajay Nooka, Jonathan L Kaufman, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapyJonathan L Kaufman, Claire Fabre, Sagar Lonial, et al.
Blood and Lymphatic Cancer : Targets and Therapy|March 19, 2021
BCL2 Family Inhibitors in the Biology and Treatment of Multiple MyelomaVikas A Gupta, James Ackley, Jonathan L Kaufman, et al.
Cancer|March 29, 2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studiesR Donald Harvey, Chao Zhang, Sagar Lonial, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case reportNicole Wilson, Minal Surati, Bruce F Walker, et al.
Pageof 15